{
    "clinical_study": {
        "@rank": "112547", 
        "arm_group": [
            {
                "arm_group_label": "Insulin 338 + placebo", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Insulin glargine + placebo", 
                "arm_group_type": "Active Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "This trial is conducted in Europe. The aim of the trial is to investigate the safety,\n      tolerability, pharmacokinetics (the exposure of the trial drug in the body) and\n      pharmacodynamics (the effect of the investigated drug on the body) of NNC0123-0000-0338\n      (insulin 338) in subjects with type 2 diabetes."
        }, 
        "brief_title": "A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes", 
        "completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "condition": [
            "Diabetes", 
            "Diabetes Mellitus, Type 2"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Diabetes Mellitus", 
                "Diabetes Mellitus, Type 2"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Male subject, or female subject of no childbearing potential, if surgically\n             sterilized (i.e. tubal ligation, bilateral oopherectomies (removal of both ovaries\n             and both fallopian tubes) or hysterectomised) for at least 3 months or if\n             postmenopausal (i.e. as defined by amenorrhoea for at least 12 months prior to\n             screening and documented by follicle stimulating hormone (FSH) levels above 40 U/L)\n\n          -  Body mass index (BMI) between 20.0 and 35.0 kg/m^2 (both inclusive)\n\n          -  Type 2 diabetes mellitus (as diagnosed clinically) for 12 months or more\n\n        Exclusion Criteria:\n\n          -  Known or suspected hypersensitivity to trial products or related products\n\n          -  Presence of clinically significant acute gastrointestinal symptoms (e.g. nausea,\n             vomiting, heartburn or diarrhoea) within 2 weeks prior to dosing, as judged by the\n             Investigator\n\n          -  Any chronic disorder or severe disease which in the opinion of the Investigator might\n             jeopardise subject's safety or compliance with the protocol"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "40", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "February 20, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01796366", 
            "org_study_id": "NN1953-4013", 
            "secondary_id": [
                "2012-003046-32", 
                "U1111-1132-0943"
            ]
        }, 
        "intervention": [
            {
                "arm_group_label": "Insulin 338 + placebo", 
                "description": "Each subject will be allocated to one of three dosing periods only. The subject will receive oral insulin 338 and placebo, administered subcutaneously (s.c., under the skin) once daily for 10 days at fixed dose levels.", 
                "intervention_name": "insulin 338 (GIPET I)", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin 338 + placebo", 
                "description": "S.c placebo administered in combination with insulin 338", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin glargine + placebo", 
                "description": "Each subject will be allocated to one of three dosing periods only. The subject will receive insulin glargine for s.c. administration and oral placebo once daily for 10 days at fixed dose levels.", 
                "intervention_name": "insulin glargine", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Insulin glargine + placebo", 
                "description": "Oral placebo administered in combination with s.c. insulin glargine", 
                "intervention_name": "placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Glargine", 
                "Insulin", 
                "Insulin, Long-Acting"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "August 20, 2013", 
        "link": {
            "description": "Clinical Trials at Novo Nordisk", 
            "url": "http://novonordisk-trials.com"
        }, 
        "location": {
            "facility": {
                "address": {
                    "city": "Neuss", 
                    "country": "Germany", 
                    "zip": "41460"
                }
            }
        }, 
        "location_countries": {
            "country": "Germany"
        }, 
        "number_of_arms": "2", 
        "official_title": "A Multiple Dose Trial Investigating the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of NNC0123-0000-0338 in Subjects With Type 2 Diabetes", 
        "overall_official": {
            "affiliation": "Novo Nordisk A/S", 
            "last_name": "Inge Birk Halberg", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Germany: Federal Institute for Drugs and Medical Devices", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "August 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of treatment emergent adverse events", 
            "safety_issue": "No", 
            "time_frame": "As recorded from first trial product administration (Day 1) and until Sub-visit 2A (Day 12) of the dosing visit"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01796366"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Area under the serum insulin concentration-time curve", 
                "safety_issue": "No", 
                "time_frame": "During one dosing interval (0-24 hours) at steady-state (Day 10)"
            }, 
            {
                "measure": "Area under the glucose infusion rate-time curve", 
                "safety_issue": "No", 
                "time_frame": "During one dosing interval (0-24 hours) at steady state (Day 10)"
            }
        ], 
        "source": "Novo Nordisk A/S", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Novo Nordisk A/S", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "February 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2013"
    }
}